Anteris Technologies (ASX:AVR) completed its initial public offering in the US, issuing 14.8 million shares at $6 each to raise gross proceeds of $88.8 million, according to a Tuesday filing with the Australian bourse.
The company's stock started trading on the Nasdaq Global Market under the ticker "AVR" on Dec. 13, the filing said.
The company will also list its Chess Depositary Interests on the Australian stock exchange under the ticker "AVR," the filing added.
The company plans to use the proceeds from the IPO to fund the development of its DurAVR transcatheter heart valve and a global clinical study for the valve to treat aortic stenosis, with remaining funds for working capital and debt repayment.
Shares of the company fell nearly 15% in recent Tuesday trade.
Price (AUD): $9.00, Change: $-1.54, Percent Change: -14.61%